The largest commercial kinase panel available, scanMAX contains a set of 468 kinases covering AGC, CAMK, CMGC, CK1, STE, TK, TKL, lipid and atypical kinase families, plus important mutant forms. scanMAX is an ideal choice for all stages of drug discovery and development, from lead discovery & hit identification to lead optimization, preclinical and compound safety.
Kinome-wide annotation of compound selectivity enables informed decisions about therapeutic opportunities and potential off-target liabilities which could otherwise be missed in smaller kinase panels. Panel includes: 453 human kinases, 3 pathogen kinases, 56 disease relevant mutants, 132 tyrosine kinase assays, and 20 lipid kinases.
Panel Features & Benefits
- More than 80% coverage of the human protein kinome
- High-quality reproducible data
- Rapid turnaround time
- Broad dynamic range: can detect compounds with Kds <100 pM >10 uM
- Flexible – Standard and custom panels
- Activation-state specific assays
- Detection of multiple inhibitor types (e.g. type I, II & non-ATP competitive)
